Buprenorphine following ketamine treatment enhances anti‐suicidal effects
The Brown University Psychopharmacology Update · 2026-09 · 37 (9) · 1-5
DOI: 10.1002/pu.31484 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 03.08.2026.
Abstract (Originalsprache)
Patients with major depressive disorder (MDD) who received 4 weeks of buprenorphine treatment following a single infusion of ketamine experienced a significant reduction in suicidal ideation compared with ketamine plus placebo, a randomized, double‐blind trial has found. No serious treatment‐related adverse events were reported. Study results were published online May 19, 2026 in the American Journal of Psychiatry .
Zitieren
APA
(2026). Buprenorphine following ketamine treatment enhances anti‐suicidal effects. The Brown University Psychopharmacology Update, 37(9), 1-5. https://doi.org/10.1002/pu.31484
Vancouver
Buprenorphine following ketamine treatment enhances anti‐suicidal effects. The Brown University Psychopharmacology Update. 2026;37(9):1-5. doi:10.1002/pu.31484
BibTeX
@article{euvimed2026,
title = {Buprenorphine following ketamine treatment enhances anti‐suicidal effects},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {9},
pages = {1--5},
doi = {10.1002/pu.31484}
}
EUVIMED